Randomized Phase III Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype patients_MITO-23
Latest Information Update: 16 Jul 2022
At a glance
- Drugs Trabectedin (Primary) ; Carboplatin; Doxorubicin liposomal; Gemcitabine; Paclitaxel; Topotecan
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms MITO23
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 24 Aug 2021 Status changed from active, no longer recruiting to completed.
- 23 Jul 2020 Planned End Date changed from 1 Apr 2020 to 1 Mar 2021.